Calciphylaxis: A Rare Clinical Presentation in a Patient with End-Stage Renal Disease (ESRD)

Adedeji Okikiade *

Clinical sciences, California Northstate University, Elk-Groove, California, USA.

Twanna Browne-Caesar

Caribbean Kidney and Medical Center, Arnos Vale, Saint Vincent and the Grenadines.

Olayinka Afolayan-Oloye

Department of Physiology, Tulane University School of Medicine, New Orleans, Los Angeles, USA.

Rasheed Agboola

Department of Bio-Medical Sciences, Philadelphia College of Osteopathic Medicine, South Georgia, Georgia, USA.

Kevin Browne

All Saint University, College of Medicine, Saint Vincent and the Grenadines.

*Author to whom correspondence should be addressed.


Calciphylaxis, also known as calcific uremic arteriolopathy (CUA), affects small arteries of the skin in patients with end-stage renal failure, dialysis patients, and patients with hypercalcemia. The condition is characterized by the calcification of small blood vessels leading to skin necrosis without inflammation. It is frequently complicated by superimposed infection and bleeding and has a high mortality rate.

The rare condition is yet to be documented on the islands of Saint Vincent and the Grenadines. The authors have, therefore, made efforts to document, educate, and discuss this rare presentation in a 65-year-old local Vincentian male with 30 years history of poorly controlled diabetes mellitus and hypertension who commenced hemodialysis two years prior to the presentation for end-stage chronic renal failure. With the increasing incidence and prevalence of diabetes mellitus, hypertension, and complications of chronic kidney disease, and renal failure, this article is written as a case study with a concise literature review on calciphylaxis to provide continuing medical education and increase the level of awareness among medical students and index of suspicion among healthcare providers.

Keywords: Calciphylaxis, calcific uremic arteriopathy, end-stage renal failure, Diabetes mellitus, Saint Vincent and the Grenadines, Thiosulphate

How to Cite

Okikiade, A., Browne-Caesar, T., Afolayan-Oloye, O., Agboola, R., & Browne, K. (2023). Calciphylaxis: A Rare Clinical Presentation in a Patient with End-Stage Renal Disease (ESRD). Advances in Research, 24(5), 18–25.


Download data is not yet available.


Chacon G, Nguyen T, Khan A, Sinha A, Maddirala S. Warfarin-induced skin necrosis mimicking calciphylaxis: A case report and review of the literature. Journal of Drugs in Dermatology. 2010;9(7): 859–863.

Hayden MR, Goldsmith DJ. Sodium thiosulfate: New hope for the treatment of calciphylaxis. Semin Dial. 2010;23: 258–262.

Luo G, Ducy P, McKee MD, Pinero GJ, Loyer E, Behringer RR, Karsenty G: Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 1997;386:78–81.

Fiona Larsen, Dept of Dermatology Greenlane Hospital Auckland, 2004. Calciphylaxis: DERM.NET.NZ Updated by A/Prof Amanda Oakley, February; 2016.

Torregrosa JV, Durán CE, Barros X, Blasco M, Arias M, Cases A, et al. X. Successful treatment of calcific uraemic arteriolopathy with bisphosphonates. Nephrology. 2012;32:329–334.

Nigwekar SU, Thadhani R, Brandenburg VM. "Calciphylaxis". New England Journal of Medicine. 2018;378(18):1704–1714.

Nigwekar SU, Wolf M, Sterns RH, Hix JK. Calciphylaxis from nonuremic causes: a systematic review. Clinical Journal of the American Society of Nephrology: CJASN. 2008;3(4):1139–1143.

Bkiri S, Tlemsani Z, Khdach Y, Nmili Y, Bennani K, Abbad F, Ghadouane M. Penile calciphylaxis in a patient with end-stage renal disease and chronic hemodialysis: a case report. Pan Afr Med J. 2022;43:136.

DOI: 10.11604/pamj.2022.43.136.37673. PMID: 36762167; PMCID: PMC9898768

Khoruts A, Stahnke L, McClain CJ, Logan G, Allen JI: Circulating tumor necrosis factor, interleukin-1 and interleukin-6 concentrations in chronic alcoholic patients. Hepatology. 1991;13:267–276.

Wolff, Klaus; Johnson, Richard; Saavedra, Arturo. Fitzpatrick's Color Atlas and Synopsis of Clinical Dermatology (7th ed.). McGraw Hill. 2013;429

Hamedoun L, Mohamed T. Penile calciphylaxis: rare and unrecognized disease. Pan Afr Med J. 2022;41:124.

DOI: 10.11604/pamj.2022.41.124.33602. PMID: 35480413; PMCID: PMC9011911

Moe SM, Reslerova M, Ketteler M, O'neill K, Duan D, Koczman J, Westenfeld R, Jahnen-Dechent W, Chen NX. Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease (CKD). Kidney Int. 2005;67(6): 2295-304. DOI: 10.1111/j.1523-1755.2005.00333.x. PMID: 15882271

Rashid RM, Hauck M, Lasley M (Nov). Anti-nuclear antibody: a potential predictor of calciphylaxis in non-dialysis patients. J Eur Acad Dermatol Venereol. 2008;22(10):1247–8

Cai MM, Smith ER, Brumby C, McMahon LP, Holt SG. Fetuin-A-containing calciprotein particle levels can be reduced by dialysis, sodium thiosulphate, and plasma exchange. Potential therapeutic implications for calciphylaxis? Nephrology (Carlton). 2013;18(11):724-7. DOI: 10.1111/nep.12137. PMID: 24571743

Bardin T. Musculoskeletal manifestations of chronic renal failure. Curr Opin Rheumatol. 2003;15(1):48-54.

DOI 10.1097/00002281-200301000-00009. PMID: 12496510

Ma YL, Cain RL, Halladay DL, Yang X, Zeng Q, Miles RR, Chandrasekhar S, Martin TJ, Onyia JE: Catabolic effects of continuous human PTH (1e38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. Endocrinology. 2001;142:4047–4054.

Huang L, Xu J, Kumta SM, Zheng MH: Gene expression of glucocorticoid receptor a and b in giant cell tumour of bone: Evidence of glucocorticoid-stimulated osteoclastogenesis by stromal-like tumour cells. Mol Cell Endocrinol. 2001;181: 199–206.

Win KM, Castelhano R, Dasgupta T. Concurrent development of encapsulating peritoneal sclerosis and calciphylaxis in a patient with peritoneal dialysis for end-stage renal disease. BMJ Case Reports CP. 2022;15(3):e245156.

Calciphylaxis. (February 27). In Wikipedia; 2023.


Kodumudi V, Jeha GM, Mydlo N, Kaye AD. Management of Cutaneous Calciphylaxis. Adv Ther. 2020;37(12):4797-4807. DOI: 10.1007/s12325-020-01504-w. Epub 2020 Sep 30. PMID: 32997277; PMCID: PMC7595979

Bachu R, Patel TH, Hemmings S. Calciphylaxis in End-Stage Renal Disease: A Rare Condition With High Mortality. Cureus. 2022;14(7):e26752. DOI: 10.7759/cureus.26752. PMID: 35967146; PMCID: PMC9363687.

Ryan MP, Ross LS. Calciphylaxis After Kidney Transplant. Cureus. 2019;11(5): e4695.

DOI: 10.7759/cureus.4695. PMID: 31338270; PMCID: PMC6639085

Couri T, Stier M, Mikolajczyk A, Aronsohn A. Calciphylaxis in the end-stage liver and renal disease patients before and after transplant. Clin Transplant. 2018;32(6): e13272. DOI: 10.1111/ctr.13272. PMID: 29714030

Guillén-Olmos E, Torregrosa JV, Garcia-Herrera A, Ganau S, Diekmann F, Cucchiari D. Development of calciphylaxis in kidney transplant recipients with a functioning graft. Clin Kidney J. 2021; 15(4):663-671.

DOI: 10.1093/ckj/sfab205. PMID: 35371461; PMCID: PMC8967679

Roy S, Reddy SN, Garcha AS, Vantipalli P, Patel SS, Ur Rahman E, Adapa S. Successful Treatment of Calciphylaxis in a Young Female With End-Stage Renal Disease on Peritoneal Dialysis With Parathyroidectomy, Intensification of Dialysis, and Sodium Thiosulphate-A Case Report and Literature Review. J Investig Med High Impact Case Rep. 2021; 9:23247096211060580. DOI: 10.1177/23247096211060580. PMID: 34845938; PMCID: PMC8637396